Abstract
G protein-coupled receptors (GPCR) are a superfamily of receptors that are vital in a wide array of physiological processes. Modulation of GPCR signaling has been an intensive area of therapeutic study, mainly due to the diverse pathophysiological significance of GPCRs. Pepducins are cell-penetrating lipidated peptides designed to target the intracellular loops of the GPCR of interest. Pepducins can function as agonists or antagonists of their cognate receptor, making them highly useful compounds for the study of GPCR signaling. Pepducins have been used to control platelet-dependent hemostasis and thrombosis, tumor growth, invasion, and angiogenesis, as well as to improve sepsis outcomes in mice. Pepducins have been successfully designed against a wide variety of GPCRs including the protease-activated receptors (PAR1, 2, 4), the chemokine receptors (CXCR1, 2, 4), the sphingosine-1-phosphate receptor (S1P3), the adrenergic receptor (ADRA1B), and have the potential to help reveal the functions of intractable GPCRs. Pharmacokinetic, pharmacodynamic, and biodistribution studies have showed that pepducins are widely distributed throughout the body except the brain and possess appropriate drug-like properties for use in vivo. Here, we discuss the delivery, pharmacology, and biodistribution of pepducins, as well as the effects of pepducins in models of inflammation, cardiovascular disease, cancer, and angiogenesis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor, Science 289, 739–745.
Covic, L., Misra, M., Badar, J., Singh, C., and Kuliopulos, A. (2002) Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation, Nat Med 8, 1161–1165.
Kuliopulos, A., and Covic, L. (2003) Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis, Life Sci 74, 255–262.
Covic, L., Gresser, A. L., Talavera, J., Swift, S., and Kuliopulos, A. (2002) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides, Proc Natl Acad Sci USA 99, 643–648.
Keuren, J. F., Wielders, S. J., Ulrichts, H., Hackeng, T., Heemskerk, J. W., Deckmyn, H., Bevers, E. M., and Lindhout, T. (2005) Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1, Arterioscler Thromb Vasc Biol 25, 1499–1505.
Leger, A. J., Jacques, S. L., Badar, J., Kaneider, N. C., Derian, C. K., Andrade-Gordon, P., Covic, L., and Kuliopulos, A. (2006) Blocking the protease-activated receptor 1–4 heterodimer in platelet-mediated thrombosis, Circulation 113, 1244–1254.
Trivedi, V., Boire, A., Tchernychev, B., Kaneider, N. C., Leger, A. J., O’Callaghan, K., Covic, L., and Kuliopulos, A. (2009) Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site, Cell 137, 332–343.
Majumdar, M., Tarui, T., Shi, B., Akakura, N., Ruf, W., and Takada, Y. (2004) Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin alpha(9)beta(1), J Biol Chem 279, 37528–37534.
Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., and Kuliopulos, A. (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells, Cell 120, 303–313.
Remsberg, J. R., Lou, H., Tarasov, S. G., Dean, M., and Tarasova, N. I. (2007) Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth, J Med Chem 50, 4534–4538.
Kaneider, N. C., Agarwal, A., Leger, A. J., and Kuliopulos, A. (2005) Reversing systemic inflammatory response syndrome with chemokine receptor pepducins, Nat Med 11, 661–665.
Kaneider, N. C., Leger, A. J., Agarwal, A., Nguyen, N., Perides, G., Derian, C., Covic, L., and Kuliopulos, A. (2007) ‘Role reversal’ for the receptor PAR1 in sepsis-induced vascular damage, Nat Immunol 8, 1303–1312.
Licht, T., Tsirulnikov, L., Reuveni, H., Yarnitzky, T., and Ben-Sasson, S. A. (2003) Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3), Blood 102, 2099–2107.
Edwards, R. J., Moran, N., Devocelle, M., Kiernan, A., Meade, G., Signac, W., Foy, M., Park, S. D., Dunne, E., Kenny, D., and Shields, D. C. (2007) Bioinformatic discovery of novel bioactive peptides, Nat Chem Biol 3, 108–112.
Shpakov, A. O., Pertseva, M. N., Guryanov, I. A., and Vlasov, G. P. (2005) Influence of synthetic peptides derived from the third cytoplasmic loop of the type 1 relaxin receptor on the stimulation of G-protein GTP-binding activity by relaxin, Biol Membrany 22, 450–457.
Swift, S., Leger, A. J., Talavera, J., Zhang, L., Bohm, A., and Kuliopulos, A. (2006) Role of the PAR1 receptor 8th helix in signaling: the 7-8-1 receptor activation mechanism, J Biol Chem 281, 4109–4116.
Shpakov, A. O., Gur’yanov, I. A., Kuznetsova, L. A., Plesneva, S. A., Shpakova, E. A., Vlasov, G. P., and Pertseva, M. N. (2007) Studies of the molecular mechanisms of action of relaxin on the adenylyl cyclase signaling system using synthetic peptides derived from the LGR7 relaxin receptor, Neurosci Behav Physiol 37, 705–714.
Wielders, S. J., Bennaghmouch, A., Reutelingsperger, C. P., Bevers, E. M., and Lindhout, T. (2007) Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists, J Thromb Haemost 5, 571–576.
Covic, L., Tchernychev, B., Jacques, S., and Kuliopulos, A. (2007) Pharmacology and In Vivo Efficacy of Pepducins in Hemostasis and Arterial Thrombosis, in Handbook of Cell-Penetrating Peptides (Langel, U., Ed.), pp. 245–257, CRC Press, Boca Raton, FL.
Hollenberg, M. D., Saifeddine, M., Sandhu, S., Houle, S., and Vergnolle, N. (2004) Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo, Br J Pharmacol 143, 443–454.
Slofstra, S. H., Bijlsma, M. F., Groot, A. P., Reitsma, P. H., Lindhout, T., ten Cate, H., and Spek, C. A. (2007) Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation, Blood 110, 3176–3182.
Houle, S., Papez, M. D., Ferazzini, M., Hollenberg, M. D., and Vergnolle, N. (2005) Neutrophils and the kallikrein–kinin system in proteinase-activated receptor 4-mediated inflammation in rodents, Br J Pharmacol 146, 670–678.
Zhang, G., Kernan, K. A., Collins, S. J., Cai, X., Lopez-Guisa, J. M., Degen, J. L., Shvil, Y., and Eddy, A. A. (2007) Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals, J Am Soc Nephrol 18, 846–859.
Annahazi, A., Gecse, K., Dabek, M., Ait-Belgnaoui, A., Rosztoczy, A., Roka, R., Molnar, T., Theodorou, V., Wittmann, T., Bueno, L., and Eutamene, H. (2009) Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice, Pain 144, 209–217.
Dabek, M., Ferrier, L., Roka, R., Gecse, K., Annahazi, A., Moreau, J., Escourrou, J., Cartier, C., Chaumaz, G., Leveque, M., Ait-Belgnaoui, A., Wittmann, T., Theodorou, V., and Bueno, L. (2009) Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis, Am J Pathol 175, 207–214.
McDougall, J. J., Zhang, C., Cellars, L., Joubert, E., Dixon, C. M., and Vergnolle, N. (2009) Triggering of proteinase-activated receptor 4 leads to joint pain and inflammation in mice, Arthritis Rheum 60, 728–737.
Hotchkiss, R. S., and Karl, I. E. (2003) The pathophysiology and treatment of sepsis, N Engl J Med 348, 138–150.
Riedemann, N. C., Guo, R. F., and Ward, P. A. (2003) Novel strategies for the treatment of sepsis, Nat Med 9, 517–524.
Sambrano, G. R., Weiss, E. J., Zheng, Y. W., Huang, W., and Coughlin, S. R. (2001) Role of thrombin signalling in platelets in haemostasis and thrombosis, Nature 413, 74–78.
Grenegard, M., Vretenbrant-Oberg, K., Nylander, M., Desilets, S., Lindstrom, E. G., Larsson, A., Ramstrom, I., Ramstrom, S., and Lindahl, T. L. (2008) The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine, J Biol Chem 283, 18493–18504.
Leger, A. J., Covic, L., and Kuliopulos, A. (2006) Protease-activated receptors in cardiovascular diseases, Circulation 114, 1070–1077.
Seehaus, S., Shahzad, K., Kashif, M., Vinnikov, I. A., Schiller, M., Wang, H., Madhusudhan, T., Eckstein, V., Bierhaus, A., Bea, F., Blessing, E., Weiler, H., Frommhold, D., Nawroth, P. P., and Isermann, B. (2009) Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability, Circulation 120, 774–784.
Kubo, S., Ishiki, T., Doe, I., Sekiguchi, F., Nishikawa, H., Kawai, K., Matsui, H., and Kawabata, A. (2006) Distinct activity of peptide mimetic intracellular ligands (pepducins) for proteinase-activated receptor-1 in multiple cells/tissues, Ann N Y Acad Sci 1091, 445–459.
Strande, J. L., Hsu, A., Su, J., Fu, X., Gross, G. J., and Baker, J. E. (2008) Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling, J Pharmacol Exp Ther 324, 1045–1054.
Dorsam, R. T., and Gutkind, J. S. (2007) G-protein-coupled receptors and cancer, Nat Rev Cancer 7, 79–94.
Even-Ram, S., Uziely, B., Cohen, P., Grisaru-Granovsky, S., Maoz, M., Ginzburg, Y., Reich, R., Vlodavsky, I., and Bar-Shavit, R. (1998) Thrombin receptor overexpression in malignant and physiological invasion processes, Nat Med 4, 909–914.
Henrikson, K. P., Jazin, E. E., Greenwood, J. A., and Dickerman, H. W. (1990) Prothrombin levels are increased in the estrogen-treated immature rat uterus, Endocrinology 126, 167–175.
Rudroff, C., Seibold, S., Kaufmann, R., Zetina, C. C., Reise, K., Schafer, U., Schneider, A., Brockmann, M., Scheele, J., and Neugebauer, E. A. (2002) Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro, Clin Exp Metastasis 19, 181–189.
Nierodzik, M. L., Chen, K., Takeshita, K., Li, J. J., Huang, Y. Q., Feng, X. S., D’Andrea, M. R., Andrade-Gordon, P., and Karpatkin, S. (1998) Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis, Blood 92, 3694–3700.
Even-Ram, S. C., Maoz, M., Pokroy, E., Reich, R., Katz, B. Z., Gutwein, P., Altevogt, P., and Bar-Shavit, R. (2001) Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin, J Biol Chem 276, 10952–10962.
Nierodzik, M. L., Kajumo, F., and Karpatkin, S. (1992) Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo, Cancer Res 52, 3267–3272.
Whitehead, I., Kirk, H., and Kay, R. (1995) Expression cloning of oncogenes by retroviral transfer of cDNA libraries, Mol Cell Biol 15, 704–710.
Martin, C. B., Mahon, G. M., Klinger, M. B., Kay, R. J., Symons, M., Der, C. J., and Whitehead, I. P. (2001) The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways, Oncogene 20, 1953–1963.
Yang, E., Boire, A., Agarwal, A., Nguyen, N., O’Callaghan, K., Tu, P., Kuliopulos, A., and Covic, L. (2009) Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis, Cancer Res 69, 6223–6231.
Agarwal, A., Covic, L., Sevigny, L. M., Kaneider, N. C., Lazarides, K., Azabdaftari, G., Sharifi, S., and Kuliopulos, A. (2008) Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer, Mol Cancer Ther 7, 2746–2757.
Kaufmann, R., Oettel, C., Horn, A., Halbhuber, K. J., Eitner, A., Krieg, R., Katenkamp, K., Henklein, P., Westermann, M., Bohmer, F. D., Ramachandran, R., Saifeddine, M., Hollenberg, M. D., and Settmacher, U. (2009) Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion, Carcinogenesis 30, 1487–1496.
Bailey, J. M., Mohr, A. M., and Hollingsworth, M. A. (2009) Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer, Oncogene 28, 3513–3525.
Theunissen, J. W., and de Sauvage, F. J. (2009) Paracrine Hedgehog signaling in cancer, Cancer Res 69, 6007–6010.
Acknowledgments
This research was supported by NIH grants CA104406 (L. Covic) and CA122992, HL64701, and HL57905 (A. Kuliopulos).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Tressel, S.L., Koukos, G., Tchernychev, B., Jacques, S.L., Covic, L., Kuliopulos, A. (2011). Pharmacology, Biodistribution, and Efficacy of GPCR-Based Pepducins in Disease Models. In: Langel, Ü. (eds) Cell-Penetrating Peptides. Methods in Molecular Biology, vol 683. Humana Press. https://doi.org/10.1007/978-1-60761-919-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-60761-919-2_19
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-918-5
Online ISBN: 978-1-60761-919-2
eBook Packages: Springer Protocols